NEWS UPDATE

ABOUT US

Better Medicine
for a Brighter Tomorrow

‘Sol’ means the Sun and
‘Asia’ the Asian counties in Spanish.
We desire to be the Sun brightening the future of
various people facing many challenges of
cancers in Japan and other Asian countries.

Solasia
at a Glance

View

DEVELOPMENT STATUS

PRODUCTS

PIPELINES INDICATION AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

Sancuso®(SP-01)

MORE INFO
Chemotherapy Induced Nausea and Vomiting (CINV) China
Launched in 2019 Preparing to apply for change of manufacturing facility

 

 

Lee’s Pharm:
All China

DARVIAS® (SP-02)

MORE INFO
Peripheral T-Cell Lymphoma (PTCL) Japan
Launched in August 2022  Began searching for additional indications

Nippon Kayaku:
Japan


HB Human BioScience:
Latin America

South Korea, Taiwan, Hong Kong
Phase II (pivotal) study completed Out-licensing activities ongoing
South America
Preparations to file for approval underway in each country based on approval granted in Japan(Colombia has already filed.)
China
Development strategy being drafted based on US study data and approval in Japan; out-licensing activity ongoing
US
Early Phase II study completed; out-licensing activity ongoing
EU
NPP strategy being launched

episil® oral liquid(SP-03)

MORE INFO
Pain associated oral mucositis [Medical Device] Japan
Launched in 2018

Meiji Seika Pharma:

Japan

 

Lee’s Pharm:
All China

 

Synex
South Korea

China
Launched in 2019
South Korea
Launched in 2020

PIPELINES

PIPELINES TARGET
INDICATION
AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

SP-04

MORE INFO
Chemotherapy Induced Peripheral Neuropathy (CIPN) Japan etc.
Pre-clinical study in taxane-induced peripheral neuropathy

Maruho:
Japan

CEO Message

View

Corporate
Overview/History

View

PAGE TOP